Personalis, Inc.

Equities

PSNL

US71535D1063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.49 USD +2.76% Intraday chart for Personalis, Inc. +2.05% -29.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring CI
Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating MT
Transcript : Personalis, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M MT
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 CI
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Personalis to Offer ClearNote's Epigenomic Platform in Partnership MT
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology CI
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay CI
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test MT
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing CI
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform MT
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers CI
Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating MT
Transcript : Personalis, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (PSNL) PERSONALIS Posts Q3 Revenue $18.2M, vs. Street Est of $17M MT
Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023 CI
Personalis, Inc. Revises Earnings Guidance for the Full Year 2023 CI
Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer CI
Transcript : Personalis, Inc. - Special Call
Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study CI
Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance CI
Chart Personalis, Inc.
More charts
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.49 USD
Average target price
4.75 USD
Spread / Average Target
+218.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Personalis, Inc. - Nasdaq
  4. News Personalis, Inc.
  5. Personalis : Citigroup Adjusts Personalis' Price Target to $30 From $37, Maintains Buy Rating